Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | NPC1 | O15118 | 4/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | MMP13 | P45452 | 8/20 | 0.58 |
| ▸ | MMP2 | P08253 | 6/20 | 0.58 |
| ▸ | MMP14 | P50281 | 4/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29721945 | 1.00 | RAB9A (0.64) | RAB9AKDM4EALDH1A1NPC1HPGD | |
| SCHEMBL4395681 | 0.82 | KDM4E (0.54) | KDM4EALDH1A1HPGDLMNAMAPT | |
| SCHEMBL29721979 | 0.82 | KDM4E (0.54) | KDM4EALDH1A1HPGDLMNAMAPT | |
| SCHEMBL2108919 | 0.80 | KDM4E (0.61) | RAB9AKDM4EALDH1A1NPC1HPGD | |
| SCHEMBL419130 | 0.80 | MMP13 (0.77) | RAB9AKDM4EALDH1A1NPC1HPGD | |
| SCHEMBL9081991 | 0.79 | KDM4E (0.59) | RAB9AKDM4EALDH1A1NPC1HPGD | |
| SCHEMBL22777811 | 0.79 | KDM4E (0.51) | KDM4EALDH1A1HPGDLMNAMAPT | |
| SCHEMBL29448120 | 0.79 | KDM4E (0.51) | KDM4EALDH1A1HPGDLMNAMAPT | |
| SCHEMBL5567460 | 0.79 | KDM4E (1.00) | RAB9AKDM4EALDH1A1NPC1HPGD | |
| SCHEMBL4266823 | 0.78 | KDM4E (0.58) | RAB9AKDM4EALDH1A1NPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002372-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-20230002372-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2023-01-05 | — | — | US | disclosed |
| EP-4034108-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | The Global Alliance for TB Drug Development, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| WO-2021062316-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| WO-2021062316-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| US-20100249183-A1 | THERAPEUTIC USE OF N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | US | disclosed |
| US-7763636-B2 | N-(arylalkyl)-1H-pyrrolopyridine-2-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-07-27 | — | — | US | disclosed |
| US-20080125459-A1 | N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125459-A1 | N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | CYP3A5, ZYX, ZDHHC2 | RAB9A 1589/4885KDM4E 1484/4885ALDH1A1 208/4885 |
| US-20230002372-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | AZI2, AADAC, TPMT | RAB9A 1442/4885KDM4E 1203/4885ALDH1A1 675/4885 |
| US-20100249183-A1 | THERAPEUTIC USE OF N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES | ZDHHC2, ZYX, GLS2 | RAB9A 1911/4885KDM4E 1925/4885ALDH1A1 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.